Participants
Eligible participants were between 5-21 years old with newly diagnosed ALL (B- or T-cell) and fluent in English or Spanish. All participants were enrolled within three days of starting induction therapy. Consent and assent, when applicable, were obtained from parents and participants. Participants were removed from the study if they relapsed, deceased, or left the institution.